

Useful Information That May Be Gleaned From The Nationwide Exenatide Audit

This might include:

- How much **weight loss** occurs with Exenatide in real clinical use.
- How much **HbA1c reduction** occurs with Exenatide in real clinical use.
- Who are the patients **who respond** especially well to Exenatide in real clinical use – does it relate to duration of diabetes, or body mass index, or particular other medications being used etc. Is it possible to predict the patients who are more likely to respond to Exenatide.
- Similarly, who are the patients **who don't respond** to Exenatide?
- Currently Exenatide **usage with insulin** is off license but many diabetologists have tried it with insulin. The nationwide audit affords an opportunity to pool experience of usage of Exenatide with insulin across the nation, find out how useful this approach is, the extent to which insulin dose is reduced or insulin is even stopped. The data may help bring forward the licensing of usage of Exenatide with insulin.
- Is **pancreatitis** a real issue with Exenatide?
- What are the **side effects**? Are there any important ones that have not yet been identified?
- If there are problems with Exenatide which may come out in due course as possibly may occur with Rosiglitazone, can we get some **forewarning of any possible problems** now through pooling the national experience.
- To what extent does Exenatide allow **avoidance of insulin** and continuation in their jobs for **professional drivers**?
- What is the size of the problem of **hypoglycaemia** with Exenatide and insulin, or Exenatide and sulphonylureas. Is there a problem of worsening hyperglycaemia if insulin is stopped and Exenatide started? Are there guidelines that can be deduced from the nationwide experience with regard to how to add Exenatide to insulin and how to add Exenatide to sulphonylureas without inducing hypoglycaemia or hyperglycaemia.
- What percentage of patients **cannot tolerate Exenatide** in real clinical use?
- Is the clinical efficacy of Exenatide **sustained**? Does the weight loss continue with time or does it plateau off?
- Are there benefits, or otherwise, in combining of **thiazolidinediones** and exenatide
- Could we, from the data, calculate the potential benefit in terms of predicting **cardiovascular event reduction** on the as yet unvalidated assumption that the reduction in risk factors is translated into prevention of cardiovascular events?